Literature DB >> 23136913

Update on rifampin, rifabutin, and rifapentine drug interactions.

Anne M Baciewicz1, Cary R Chrisman, Christopher K Finch, Timothy H Self.   

Abstract

BACKGROUND: Rifampin is a potent inducer of both cytochrome P-450 oxidative enzymes and the P-glycoprotein transport system. Among numerous well documented, clinically significant interactions, examples include warfarin, oral contraceptives, itraconazole, digoxin, verapamil, simvastatin, and human immunodeficiency virus-related protease inhibitors. Rifabutin reduces serum concentrations of antiretroviral agents, but less so than rifampin. Rifapentine is also an inducer of drug metabolism.
METHODS: A literature search of English language journals from 2008 to March 2012 was completed using several databases, including PubMed, EMBASE, and SCOPUS. Search terms included rifampin, rifabutin, rifapentine AND drug interactions.
FINDINGS: Examples of clinically relevant interactions with rifampin demonstrated by recent reports include posaconazole, voriconazole, oxycodone, risperidone, mirodenafil, and ebastine.
CONCLUSIONS: To avoid a reduced therapeutic response, therapeutic failure, or toxic reactions when rifampin, rifabutin, or rifapentine are added to or discontinued from medication regimens, clinicians need to be aware of these interactions. Recent studies have indicated that other transporter systems play a role in these drug interactions. As reports of rifampin drug interactions continue to grow, this review is a reminder to clinicians to be vigilant.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23136913     DOI: 10.1185/03007995.2012.747952

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  55 in total

Review 1.  Management of nontuberculous mycobacterial infection in the elderly.

Authors:  Mehdi Mirsaeidi; Maham Farshidpour; Golnaz Ebrahimi; Stefano Aliberti; Joseph O Falkinham
Journal:  Eur J Intern Med       Date:  2014-03-29       Impact factor: 4.487

2.  High Mortality and Coinfection in a Prospective Cohort of Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome Patients with Histoplasmosis in Guatemala.

Authors:  Blanca Samayoa; Monika Roy; Angela Ahlquist Cleveland; Narda Medina; Dalia Lau-Bonilla; Christina M Scheel; Beatriz L Gomez; Tom Chiller; Eduardo Arathoon
Journal:  Am J Trop Med Hyg       Date:  2017-07       Impact factor: 2.345

3.  Effect of gemfibrozil and rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects.

Authors:  Shirin Bruderer; Marc Petersen-Sylla; Margaux Boehler; Tatiana Remeňová; Atef Halabi; Jasper Dingemanse
Journal:  Br J Clin Pharmacol       Date:  2017-08-16       Impact factor: 4.335

4.  Effect of a single-dose rifampin on the pharmacokinetics of pitavastatin in healthy volunteers.

Authors:  Yao Chen; Wei Zhang; Wei-hua Huang; Zhi-rong Tan; Yi-cheng Wang; Xi Huang; Hong-Hao Zhou
Journal:  Eur J Clin Pharmacol       Date:  2013-07-07       Impact factor: 2.953

5.  Inhibitory Effects of Selected Antituberculosis Drugs on Common Human Hepatic Cytochrome P450 and UDP-glucuronosyltransferase Enzymes.

Authors:  Lei Cao; David J Greenblatt; Awewura Kwara
Journal:  Drug Metab Dispos       Date:  2017-06-29       Impact factor: 3.922

6.  Casein Kinase 2 (CK2)-mediated Phosphorylation of Hsp90β as a Novel Mechanism of Rifampin-induced MDR1 Expression.

Authors:  So Won Kim; Md Hasanuzzaman; Munju Cho; Ye Rang Heo; Min-Jung Ryu; Na-Young Ha; Hyun June Park; Hyung-Yeon Park; Jae-Gook Shin
Journal:  J Biol Chem       Date:  2015-05-20       Impact factor: 5.157

7.  Effect of rifampin and rifabutin on serum itraconazole levels in patients with chronic pulmonary aspergillosis and coexisting nontuberculous mycobacterial infection.

Authors:  Seong Mi Moon; Hye Yun Park; Byeong-Ho Jeong; Kyeongman Jeon; Soo-Youn Lee; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2014-10-13       Impact factor: 5.191

Review 8.  Repositioning rifamycins for Mycobacterium abscessus lung disease.

Authors:  Uday S Ganapathy; Véronique Dartois; Thomas Dick
Journal:  Expert Opin Drug Discov       Date:  2019-06-14       Impact factor: 6.098

Review 9.  Rifampin-accompanied antibiotic regimens in the treatment of prosthetic joint infections: a frequentist and Bayesian meta-analysis of current evidence.

Authors:  Ozlem Aydın; Pinar Ergen; Burak Ozturan; Korhan Ozkan; Ferhat Arslan; Haluk Vahaboglu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-10-30       Impact factor: 3.267

10.  Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Thomas F Patterson; George R Thompson; David W Denning; Jay A Fishman; Susan Hadley; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; M Hong Nguyen; Brahm H Segal; William J Steinbach; David A Stevens; Thomas J Walsh; John R Wingard; Jo-Anne H Young; John E Bennett
Journal:  Clin Infect Dis       Date:  2016-06-29       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.